-
Allergan Sales, LLC v. Sandoz, Inc. DC CAFC
- 2:15-cv-00347
- E.D. Tex.
- Judge: Rodney Gilstrap
- Filed: 03/09/2015
- Closed: 12/30/2016
- Latest Docket Entry: 06/06/2018
- PACER
- Docket updated daily
1
Plaintiff
1
Defendant
1
Accused
Product
4
Patents-in-Suit
663
Days in
Litigation
-
Allergan Sales, LLC v. Sandoz, Inc. DC CAFC
- 2:15-cv-00347
- E.D. Tex.
- Judge: Rodney Gilstrap
- Filed: 03/09/2015
- Closed: 12/30/2016
- Latest Docket Entry: 06/06/2018
- PACER
- Docket updated daily
Market Sector
Biotech and Pharma
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
Claim # | Claim Text | Outcome |
---|---|---|
1 |
A method of treating glaucoma or ocular hypertension which comprises topically administering a therapeutically effective amount of a single composition comprising brimonidine at a concentration of about 0.2% by weight and timolol at a concentration
view more
|
Valid (102 and 103 and 112)
Entry 51 |
Claim # | Claim Text | Outcome |
---|---|---|
4 |
A method of reducing the number of daily topical ophthalmic doses of brimondine administered topically to an eye of a person in need thereof for the treatment of glaucoma or ocular hypertension from 3 to 2 times a day without loss of efficacy,
view more
|
Valid (102 and 103 and 112)
Entry 51 |
Claim # | Claim Text | Outcome |
---|---|---|
1 |
A method of treating a patient with glaucoma or ocular hypertension comprising administering twice daily to an affected eye a single composition comprising 0.2% w/v brimonidine tartrate and 0.5% w/v timolol free base, wherein said method reduces the
view more
|
Valid (102 and 103 and 112)
Entry 51 |
2 |
The method of claim 1, wherein the adverse event is conjunctival hyperemia.
|
Valid (102 and 103 and 112)
Entry 51 |
3 |
The method of claim 1, wherein the adverse event is oral dryness.
|
Valid (102 and 103 and 112)
Entry 51 |
4 |
The method of claim 1, wherein the adverse event is eye pruritus.
|
Valid (102 and 103 and 112)
Entry 51 |
5 |
The method of claim 1, wherein the adverse event is allergic conjunctivitis.
|
Valid (102 and 103 and 112)
Entry 51 |
6 |
The method of claim 1, wherein the adverse event is foreign body sensation.
|
Valid (102 and 103 and 112)
Entry 51 |
7 |
The method of claim 1, wherein the adverse event is conjunctival folliculosis.
|
Valid (102 and 103 and 112)
Entry 51 |
8 |
The method of claim 1, wherein the adverse event is somnolence.
|
Valid (102 and 103 and 112)
Entry 51 |
-
Infringement
Sandoz Inc.
- 3 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
0.2%brimonidine tartrate0.5% brimonidine tartrateGeneric 0.2%/0.5% Brimonidine TartrateGeneric 0.2%/0.5% Timolol Maleate Ophthalmic Solutiontimolol maleate ophthalmic solution | US 7,030,149 B2 |
4
|
No infringement
Entry 50Entry 51 |
0.2%brimonidine tartrate0.5% brimonidine tartrateGeneric 0.2%/0.5% Brimonidine TartrateGeneric 0.2%/0.5% Timolol Maleate Ophthalmic Solutiontimolol maleate ophthalmic solution | US 7,320,976 B2 |
1
|
No infringement
Entry 50Entry 51 |
0.2%brimonidine tartrate0.5% brimonidine tartrateGeneric 0.2%/0.5% Brimonidine TartrateGeneric 0.2%/0.5% Timolol Maleate Ophthalmic Solutiontimolol maleate ophthalmic solution | US 8,748,425 B2 |
1, 2, 3, 4, 5, 6, 7, 8
|
Infringement
Entry 50Entry 51 |